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Malaria remains a serious health problem because resistance develops to all currently used
drugs when their parasite targets mutate. Novel antimalarial drug targets are urgently needed
to reduce global morbidity and mortality. Our prior results suggested that inhibiting
erythrocyte Gs signaling blocked invasion by the human malaria parasite Plasmodium
falciparum.
Methods and Findings
We investigated the erythrocyte guanine nucleotide regulatory protein Gs as a novel
antimalarial target. Erythrocyte ‘‘ghosts’’ loaded with a Gs peptide designed to block Gs
interaction with its receptors, were blocked in b-adrenergic agonist-induced signaling. This
finding directly demonstrates that erythrocyte Gs is functional and that propranolol, an
antagonist of G protein–coupled b-adrenergic receptors, dampens Gs activity in erythrocytes.
We subsequently used the ghost system to directly link inhibition of host Gs to parasite entry. In
addition, we discovered that ghosts loaded with the peptide were inhibited in intracellular
parasite maturation. Propranolol also inhibited blood-stage parasite growth, as did other b2-
antagonists. b-blocker growth inhibition appeared to be due to delay in the terminal schizont
stage. When used in combination with existing antimalarials in cell culture, propranolol
reduced the 50% and 90% inhibitory concentrations for existing drugs against P. falciparum by
5- to 10-fold and was also effective in reducing drug dose in animal models of infection.
Conclusions
Together these data establish that, in addition to invasion, erythrocyte G protein signaling is
needed for intracellular parasite proliferation and thus may present a novel antimalarial target.
The results provide proof of the concept that erythrocyte Gs antagonism offers a novel strategy
to fight infection and that it has potential to be used to develop combination therapies with
existing antimalarials.
The Editors’ Summary of this article follows the references.
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Plasmodium falciparum is a protozoan parasite that causes the
most lethal form of malaria, a major human disease urgently
in need of new targets for future antimalarial drugs.
Targeting the blood stages of infection is particularly
important since these stages are responsible for all of the
symptoms and pathologies associated with the disease.
Increased resistance to antimalarial drugs is inevitably linked
to mutation of parasite targets and reﬂects the general
problem of continual emergence of resistance to drugs
developed against microbial targets. Indeed, the discovery
of drugs and targets that minimize the likelihood of drug-
resistant microorganisms was recognized as a Grand Chal-
lenge in Global Health [1]. One strategy is to target critical
host determinants needed for infection.
During P. falciparum blood-stage infection, the extracellular
merozoite adheres to erythrocytes, and invades and develops
intracellularly, surrounded by a parasitophorous vacuolar
membrane. Merozoites that do not invade die, and thus
erythrocytic infection is critical for parasite proliferation. In
contrast to most cells, mature erythrocytes do not possess
active endocytic machinery. Thus, malarial invasion was long
considered to be dependent mainly on parasite factors
released from invasive organelles of merozoites (i.e., rhop-
tries, dense granules, micronemes) [2]. However, a recent
study showed that components enriched in erythrocyte
detergent-resistant membrane lipid rafts are also involved
in invasion [3]. At least 25 erythrocyte proteins reside in lipid
rafts, and 12 of these are recruited to the parasitophorous
vacuolar membrane, including two well-studied signaling
proteins: the b2-adrenergic receptor (b2-AR) and its associ-
ated heterotrimeric G protein, Gs ([4–7]; SCM and KH,
personal communication).
Accordingly, Harrison and coworkers found that b-adre-
nergic receptor (b-AR) and adenosine-receptor agonists
(isoproterenol and 59-N-ethylcarboxamidoadenosine, respec-
tively), stimulated malarial entry into erythrocytes, while the
respective antagonists (propranolol and 8-(p-sulfophenyl)th-
eophilline) reversed agonist-induced stimulation of entry [7].
However, Plasmodium is a eukaryote and shares many cellular
mechanisms with its host. In addition, erythrocytes are
terminally differentiated cells, their signaling mechanisms
are not well understood, and direct evidence that erythrocyte
G proteins are active is not available. Thus, the ﬁnding that a
peptide designed to inhibit host Gs function by blocking its
interaction with host G-protein–coupled receptors (GPCRs)
reduced invasion was important to the idea that erythrocyte
Gs signaling regulated malarial invasion, even though P.
falciparum lacks conserved heterotrimeric G proteins [7].
However, the peptide does not enter uninfected erythrocytes,
and hence there is no evidence that it blocks endogenous
erythrocyte Gs signaling. Furthermore, invasion alone is not
considered a strong target for antimalarials because it is rapid
(occurring in minutes). Agents that block invasion have a
narrow window in which to act on the parasite and hence may
reduce parasitemia, but may fail to quickly eradicate the
parasite. Whether host Gs is needed for intracellular parasite
growth as well as invasion, and may thus present a target for
antimalarials, was not known.
In this paper we describe the development of erythrocyte
‘‘ghosts’’ that are active in b-adrenergic signaling and which
closely mimic normal erythrocytes in supporting P. falciparum
growth in culture. We used this system to investigate
cytoplasmic erythrocyte molecules important in erythrocyte
function, malarial entry, and intracellular growth and to
determine whether such host molecules may serve as useful
targets for antimalarial drug development.
Methods
Materials
Gs,G scr,G i, and Gq peptides were described previously [7],
although Gs and Gscr peptides were obtained from the Protein
Chemistry Core at Baylor College of Medicine (Houston,
Texas, United States). All peptides were lyophilized and
resuspended in culture medium before being added to cell
cultures. Adenosine 59-triphosphate (ATP), guanosine 59-
triphosphate (GTP), 70-kDa ﬂuorescein isothiocyanate
(FITC)–dextran, rhodamine-dextran, and drugs were from
Sigma (http://www.sigmaaldrich.com). Lucifer yellow (LY),
lucifer yellow-dextran (LY-D), and antibodies speciﬁc for
glutathione S-transferase (GST, A5800) and green ﬂuorescent
protein (GFP, A6455) were from Invitrogen (http://www.
invitrogen.com). Other chemicals were reagent-grade prod-
ucts from standard sources.
Preparation of Erythrocyte Ghosts and Loading of Cargo
Non-outdated blood obtained from LifeSource (http://www.
lifesource.org) or from consenting adult donors (Northwest-
ern University Institutional Review Board approval number
1425–002) was washed and erythrocytes were resuspended to
50% hematocrit (Hct) in cold PBS-glucose containing 1 mM
ATP and a variety of cargoes. FITC- or rhodamine-labeled 70-
kDa dextran (ﬁnal concentration 1.0–2.5 mg/ml) were used as
surrogate loading markers when non-ﬂuorescent cargoes
were loaded. Samples were chilled on ice and dialyzed with
stirring against ice-cold 5 mM K2HPO4 supplemented with 1
mM ATP (ﬁnal pH 7.4) for 1 h at 4 8C in pre-wetted 3.5-kDa
molecular weight cut-off (MWCO) Slide-a-lyzer dialysis
cassettes (Pierce Biotechnology, http://www.piercenet.com).
Lysis was performed in buffers   4 8C to prevent premature
membrane resealing. Lysis of erythrocytes by dialysis and
simultaneous equilibration with cargo avoided high-speed
centrifugation of membranes. Use of a 3.5-kDa MWCO
dialysis membrane minimized loss of small proteinaceous
components of the erythrocyte cytoplasm.
Lysed erythrocytes were removed from dialysis membranes
at 4 8C and were combined with one-ﬁfth by volume of
concentrated resealing buffer (475 mM KOAc, 25 mM
Na2HPO4, 25 mM MgCl2, and 237.5 mM KCl [pH 7.0], stored
at 25 8C, supplemented with 1.5 mM dithiothreitol [DTT], 1
mM ATP, and 5 mM GTP) and incubated for 1 h at 37 8C with
rotating. The ﬁnal ionic concentrations were 95 mM KOAc, 5
mM MgCl2, 5 mM Na2HPO4, 47.5 mM KCl, 0.3 mM DTT, 1
mM ATP, and 1 mM GTP. Potassium was favored in the
resealing buffer because intracellular potassium concentra-
tion is high in normal, intact cells and a potassium-rich
environment is known to be preferred by malaria parasites
[8]. ATP (1 mM) and GTP (1 mM) were added to maintain
critical nucleotide pools. Resealed ghosts were washed three
times in serum-free RPMI-1640 (RPMI) at room temperature
and resuspended to 10%–50% Hct in RPMI containing 10%
human serum (complete RPMI-1640 [cRPMI]). Ghosts pre-
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g), similar to normal erythrocytes. As indicated in Figure 1,
they were used to evaluate hematological properties, signal-
ing functions, and malarial infection. Reports indicate that
resealed ghosts can be permeable to small molecules [9,10], so
when small cargoes were used (,10 kDa), ghosts were
continuously bathed with cargo during the assays. Single
hematograms of normal and ghosted erythrocytes that
provided mean corpuscular volume (MCV), mean corpuscular
hemoglobin (MCH), and red cell distribution width (RDW)
were obtained using an automated Coulter counter (Depart-
ment of Pathology, Northwestern Memorial Hospital, Chica-
go, Illinois, United States).
Estimation of Protein and ATP Concentration
Protein concentrations were measured by bicinchonic acid
assay (Pierce) or by Bradford assay (Bio-Rad, http://www.
bio-rad.com). The concentrations of ATP in ghosts and in
normal intact erythrocytes were measured using an ATP-
determination kit (A22066, Invitrogen) according to the
manufacturer’s instructions; for each reaction, 1–10 3 10
5
cells were used per sample.
Protease-Protection Assay
Ghosts (5 3 10
7 cells per reaction) loaded with 40 lM
puriﬁed GST were incubated in a total volume of 100 llo f
PBS; samples were treated with or without 100 lg/ml of
proteinase K (Roche, http://www.roche.com) and/or 0.5%
Triton X-100 (w/v). Samples were incubated for 30 min at
37 8C, before protease activity was stopped by adding
phenylmethylsulfonyl ﬂuoride (1 mM ﬁnal, Invitrogen).
Proteins from 1 3 10
7 cells were solubilized in SDS-PAGE
sample buffer, before being separated by 12% acrylamide
SDS-PAGE and immunoblotted with GST-speciﬁc antibodies,
as previously described [4,5].
Flow Cytometry
Ghosts loaded or unloaded with 0.5 mg/ml of 70-kDa FITC-
dextran were washed three times and resuspended to 1% Hct
in PBS-glucose. FITC ﬂuorescence was measured on the gated
erythroid population using a FACS Caliber ﬂow cytometer
(Becton-Dickinson, http://www.bd.com).
Cyclic Adenosine Monophosphate Assays
Normal, intact erythrocytes or erythrocyte ghosts were
incubated in cRPMI containing media alone, 10 lM iso-
proterenol, 10 lM propranolol-DL, or both drugs in
combination, for 30 min at 37 8C in 24-well tissue-culture
plates. Cells were subsequently washed twice in cold PBS-
glucose. Cyclic adenosine monophosphate (cAMP) levels were
measured from 2.5–5.0 3 10
8 normal erythrocytes or ghosts
using a quantitative, colorimetric cAMP immunoassay kit
(Assay Designs direct cAMP immunoassay kit 900–066, http://
www.assaydesigns.com). Measured cAMP concentrations were
multiplied by 8.5 to account for the dilution of 50-ll cell
pellets into 0.1 M HCl lysis buffer. Data are expressed as pmol
cAMP per 1 3 10
8 cells.
Parasite Culture
P. falciparum strains 3D7 and FCB were cultured and
synchronized using standard techniques [11,12]. For protein
export experiments, P. falciparum 3D7 expressing P. falciparum
histidine-rich protein II (PfHRPII) fused to GFP was cultured
as previously described [13].
Invasion and Growth Assays in Culture
Mature schizont-stage cultures were synchronized using
standard Percoll density gradients. Uninfected ghosts were
incubated in cRPMI at 2%–5% Hct with 1%–3% synchron-
ized schizonts in 24-well plates under standard culture
conditions; ghosts were loaded with fusion proteins or bathed
in peptides as appropriate. When adrenergic-acting drugs
were used, they were dissolved in serum-free RPMI at 100-
fold ﬁnal concentration. Peptides were prepared as described
above. For invasion assays, Giemsa-stained thin blood smears
were made at 0 and 12–18 h post-invasion to determine
parasitemias. For morphological growth assays, ghosts or
normal erythrocytes were combined with synchronized
schizont-stage parasites and cultured as above; subsequent
trophozoite- and schizont-stage growth and reinvasion was
monitored by Giemsa-stained smears at 32, 44, and 64 h after
invasion. To test the reinvasion of normal erythrocytes by
malaria parasites in ghost cultures, parasites were cultured in
either ghosts or normal erythrocytes for 60 h and then
diluted into normal erythrocytes for an additional 50 h;
cultures were fed with fresh cRPMI and assessed by Giemsa-
stained blood smears daily.
Microscopy
Ghost preparations were evaluated for cell morphology
and loading efﬁciency by light and ﬂuorescence microscopy,
respectively. Parasitemias were determined by counting
Giemsa-stained thin blood smears; the counter was blinded
to sample identities. In experiments with ghosts, parasitemias
were corroborated by counting ﬂuorescently labeled ghosts
with Hoechst 33342–stained nuclei. Light microscopy and
image collection were carried out using a Zeiss Axioskop
upright microscope and Nuance spectral camera/un-mixing
system (Cambridge Research and Instrumentation, http://
www.cri-inc.com). Fluorescence microscopy and digital image
collection were carried out using an Olympus IX inverted
ﬂuorescence microscope and a Photometrix cooled CCD
camera (CH350/LCCD) driven by DeltaVision software
(Applied Precision, http://www.api.com) as described [6].
Effect of b-Blockers on Growth of P. falciparum In Vitro
Cultures
The inhibitory effects of adrenergic antagonists were
measured using standard [
3H]-hypoxanthine–incorporation
assays [14]. The data were regressed to transition functions
[15] using TableCurve 2D software (Systat, http://www.systat.
com); the Lorentzian cumulative transition function was
consistently the best-ﬁt function. The effects of b-blocker–
containing drug combinations on growth were tested using
ﬁxed-ratio drug-combination assays [16]. Brieﬂy, propranolol,
chloroquine, and/or artemisinin were serially diluted in 200 ll
of RPMI and added to 96-well plates with 2 3 10
7 infected
erythrocytes at 0.6% parasitemia, containing primarily
mature parasites. Cultures were incubated for 24 h under
standard conditions until reinvasion occurred. Following
invasion, 0.5 lCi of [
3H]-hypoxanthine (Amersham Bioscien-
ces, http://www.amershambiosciences.com) was added to each
well, and samples were re-incubated for 18 h. Plates were
harvested onto ﬁlters, dried, and assayed for [
3H]-hypoxan-
PLoS Medicine | www.plosmedicine.org December 2006 | Volume 3 | Issue 12 | e528 2405
Erythrocyte GS and Malarial Infectionthine. Individual 50% inhibitory concentration (IC50) values
were determined for each drug singly, and those values were
used to establish drug ratios used in combination studies.
Combined IC50 values were determined for each drug in
combination at 1:0, 3:1, 1:1, 1:3, and 0:1 ratios. A fractional
IC50 value (IC50 in combination/IC50 alone) was calculated for
each drug-combination ratio and used to plot isobolograms
[17]. The fractional IC50 values for each drug were added; a
sum .1 indicates synergism, ,1 indicates antagonism, and
equal to 1 indicates additive effects.
Effect of Propranolol on Sorbitol Sensitivity of P.
falciparum-Infected Erythrocytes
Incubation of 0–4 h rings at 10% parasitemia was
performed in 0.75 ml of 2 or 10 lM propranolol in cRPMI,
or in absence of the drug, for 30 h in 24-well plates; drug and
media were refreshed after 15 h. The contents of each well
were washed once in PBS-glucose and resuspended in 0.75 ml
of 5% sorbitol for 15 min at 37 8C (cells were gently
resuspended every 5 min throughout the incubation). At 0
and 15 min, 0.25-ml samples were removed, centrifuged for 5
min at 600 g, and 0.15 ml of the supernatant was transferred
to a well in a 96-well plate to measure hemoglobin release by
spectrophotometric absorbance at 570 nm. The remainder of
the sample (0.25 ml) was lysed by addition of 5 ll of 10%
saponin (w/v), and the absorbance of total hemoglobin
released was measured at 570 nm.
Effect of Propranolol on Protein Export in P. falciparum-
Infected Erythrocytes
Ring-stage cultures (10% parasitemia) of P. falciparum 3D7
expressing PfHRPII-GFP [13] were treated with propranolol
as described above for sorbitol assays. Drug-treated cultures
were grown for an additional 30 h, transferred to tubes and
washed twice with PBS-glucose. Cells were imaged live by
digitized ﬂuorescence microscopy to visualize export of the
tagged transgene to the infected erythrocytes [13]. Protein
export to the erythrocyte was quantiﬁed from 200 optical
sections using previously described methods [18].
Effect of Propranolol/Chloroquine Drug Combination in a
P. berghei Infection of Mice
Mouse experiments were performed with BALB/c mice and
P. berghei ANKA strain using a standard 4-d Peter’s test [19].
The IC50 of propranolol had been found previously to be ;8
mg/kg/d [7]; the IC50 of chloroquine in a chloroquine-sensitive
P. berghei strain is ;1.3–1.7 mg/kg/d [19]. Mice received 1310
7
parasites intraperitoneally on day 0, followed by daily
(chloroquine) and/or twice daily (propranolol) intraperito-
neal drug treatments on days 0–3. Treatment groups were:
control; chloroquine alone; propranolol alone; 2:1 propra-
nolol:chloroquine; 1:1 propranolol:chloroquine; and 1:2
propranolol:chloroquine. Each group consisted of ﬁve differ-
ent treatment doses with ﬁve mice per treatment dose; the
control group contained ﬁve mice. Individual IC50 values
were previously determined for each drug singly, and those
values were used to establish the drug ratios used in
subsequent studies. The range of chloroquine doses was
0.5–7.0 mg/kg/d; the range of propranolol doses was 1–96 mg/
kg/d. Blood smears were obtained by tail bleeding on day 4,
and animals were sacriﬁced. Combined and fractional IC50
values were determined for the indicated ratios, and an
isobologram was plotted as for the in vitro results.
Statistics
Results represent the mean 6 standard deviation unless
otherwise stated. All experiments were performed in tripli-
cate unless stated otherwise. Where indicated, representative
data from individual experiments are shown. Statistical
signiﬁcance was determined using the Student’s t-test.
Results
Production of Ghosts with Gs Signaling and Malarial
Infection that Closely Mimic Normal Erythrocytes
As summarized in Methods and in Figure 1, ghosts were
prepared by dialysis of erythrocytes in a low MWCO
membrane, simultaneously equilibrated with cargo and then
resealed in a potassium-rich buffer in the presence of ATP (1
Figure 1. Schematic for the Production of Ghosts with Gs Signaling and Malarial Infection that Closely Mimic Normal Erythrocytes
Erythrocytes were washed and resuspended to 50% Hct in PBS-glucose containing proteins of interest (‘‘cargo,’’ yellow spheres) as described in
Methods. The cell suspension was dialyzed against ATP-supplemented hypotonic potassium buffer, lysing cells, and allowing exogenous cargoes to
enter and endogenous cytoplasmic proteins to exit lysed cells (depicted over time as increasing extracellular hemoglobin, change in cell color from red
to pink, and loss of membrane integrity). Lysed cells were removed to cold test tubes and resealed at 37 8C for 1 h and washed three times in RPMI and
once in RPMI supplemented with 10% human serum (cRPMI) to eliminate extracellular hemoglobin, cargo, and buffer (see Methods). Ghosts prepared in
this manner were subsequently characterized in hematological, signaling, and malarial infection assays, as described in Figure 2.
doi:10.1371/journal.pmed.0030528.g001
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RPMI and cRPMI and used as described below. Non-outdated
blood was used to make erythrocyte ghosts; freshly drawn
erythrocytes were used for cAMP and malarial infection
assays. These resealed ghosts morphologically resembled
normal biconcave erythrocytes (Figure 2A). Early reports
suggested that ‘‘white’’ ghosts depleted of hemoglobin remain
permeable to small molecules [9,10]. However, ghosts
prepared by our procedure contained 40%–50% of starting
hemoglobin and maintained the millimolar levels of ATP in
which they were prepared, indicating that, at a minimum,
they retained critical energy pools. These levels were half of
those measured in intact erythrocytes (Figure 2B), but within
the range of ATP levels reported for erythrocytes [20,21].
Clinical hematogram analysis of a ghost preparation sug-
gested that they contained less hemoglobin (lower MCH),
were slightly microcytic (lower MCV), and were more
heterogeneous (higher RDW) than normal, intact erythro-
cytes (Figure 2B). The ghosts could be efﬁciently and
homogenously loaded with a variety of experimental cargoes,
such as high molecular weight rhodamine-labeled antibody
(Figure 2C), as well as with smaller cargoes (not shown) such
as low molecular weight LY (457 g/mol), 11-residue FITC-
labeled Gs and Gscr peptides, 10-kDa LY-D, and 70-kDa FITC-
dextran. Analyses of ghosts loaded with 70-kDa FITC-dextran
by ﬂow cytometry indicated that .99% of all cells were
homogenously loaded with cargo (Figure 2D). Further tests of
loading and retention of puriﬁed GST suggested that
proteinaceous cargoes at 10–20 lM could be reliably
encapsulated within ghosts and retained under culture
conditions; this GST was resistant to degradation by
exogenous protease (Figure 2E). These results indicated that
ghosts stably maintain nucleotide pools and loaded cargoes.
One of our major interests in developing reconstituted
erythrocyte ghosts was to study b-adrenergic signaling and its
regulation by Gs. This investigation required the presence of
active b-adrenergic signaling in ghosts. As shown in Figure 2F
and 2G, cAMP production stimulated in ghosts by 10 lM
Figure 2. Hematological and Signaling Characteristics and Cargo Loading of Erythrocyte Ghosts
(A) Ghosts (left) were biconcave but retained less pigment than intact erythrocytes (right); bar represents 10 lm.
(B) Ghost MCH (normal range for erythrocytes 27.5–33.5 pg/cell), MCV (normal range for erythrocytes 80–100 fl), and RDW (normal range for
erythrocytes 11.0%–15.0%) were determined using a Coulter counter (see Methods). Intracellular ATP levels were determined by luciferase-based ATP
assays (see Methods); the 95% confidence interval (CI) for ATP levels is indicated; two experiments.
(C) Ghosts loaded with high molecular weight rhodamine-labeled antibody were imaged without fixation by fluorescence microscopy; bar represents
25 lm.
(D) Flow cytometry of unloaded (white fill) and FITC-dextran–loaded ghosts (green fill) 2 h post-resealing, showed homogenous loading of cargo. For
each cell type, 100,000 gated events were captured.
(E) Western blot of GST-loaded ghosts after incubation in culture for 24 h and subsequent treatment in the presence or absence of proteinase K (Prot K)
and/or Triton X-100 (TX100); see Methods. GST was detected by GST-specific immunoblotting.
(F) cAMP production in normal, intact erythrocytes treated with isopreterenol (iso) and/or propranolol (prop) as measured by enzyme-linked
immunosorbent assay (see Methods). Error bars show 95% CI of triplicate measurements in a representative experiment. The mean baseline cAMP
concentration in control erythrocytes was 0.61 pmol cAMP (95% CI 0.20–1.01 pmol; three experiments) per 1 3 10
8 cells. Induced cAMP levels can
vary—the maximal value obtained (once) was 14.58 pmol cAMP (95% CI 13.11–16.03 pmol) per 1 3 10
8 cells.
(G) cAMP production in ghosts measured and depicted as described in (F). Error bars show 95% CI of triplicate measurements in a representative
experiment. The mean baseline cAMP concentration in control ghosts was 1.12 pmol cAMP (95% CI 0.59–1.64 pmol; three experiments) per 1 3 10
8
cells. The maximal isoproterenol-induced value obtained in a single ghost cAMP assay was 9.00 pmol cAMP (95% CI 7.37–10.62 pmol) per 1310
8 cells.
doi:10.1371/journal.pmed.0030528.g002
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seen in normal erythrocytes. This stimulation was quenched
by the addition of equimolar racemic propranolol (the
antagonist) in both cell types. Propranolol alone did not
reduce basal cAMP levels in either cell type. The basal and
isoproterenol-stimulated cAMP levels were similar to those
previously measured in erythrocytes [22,23]. These data show
that the b-adrenergic signaling pathway is active in these
ghosts.
As we were also interested in testing the effects of signaling
on malarial infection in ghosts, we next characterized ghosts
for their ability to support malarial infection. The intra-
erythrocytic lifecycle of malaria begins when extracellular
merozoites rapidly (,2 min) invade mature erythrocytes.
Intracellular ring-stage parasites result and subsequently
enlarge into trophozoites. Schizogony follows when an
average of 16 daughter parasites assemble and ﬁnally lyse
out of infected cells to invade new erythrocytes. Therefore,
ring formation provides a measurement of invasion and early
development, while the appearance of trophozoites and
schizonts indicates parasite maturation within the erythro-
cyte. In P. falciparum, this intracellular cycle lasts 48 h.
As shown, the resealed ghosts were infected by P. falciparum
(Figure 3A). Remarkably, infection occurred with the same
efﬁciency as in normal erythrocytes, and ghosts supported
normal parasite maturation at both low and high para-
sitemias (Figure 3B). In cultures containing equal numbers of
ghosts and normal erythrocytes, no preference was observed
for invasion or growth in either cell type (Figure 3C).
Furthermore, parasites in ghost cultures appeared morpho-
logically similar to their counterparts in normal erythrocytes
at the three distinct ring, trophozoite, and schizont stages
(Figure 3D). Schizonts that mature in ghosts are capable of
rupturing and reinvading ghosts (Figure 3E). Furthermore,
parasites grown in either ghosts or normal erythrocytes when
sub-cultured into normal erythrocytes showed no difference
in growth over the next infective cycle (Figure 3E). Over three
life cycles, completion of maturation of parasites in ghosts
can extend from 48 to 54 h per cycle (unpublished data). We
do not know why this occurs, but it is within an acceptable
range of the asexual life cycle in normal P. falciparum cultures.
Collectively, these data show that erythrocyte ghosts, active
in supporting b-adrenergic signaling and malarial invasion
and growth, can be produced and stably loaded with
exogenous cargo. Remarkably, the ghosts are essentially
equivalent to normal erythrocytes in a number of critical
respects, suggesting they may be useful for investigating
multiple functions of the human erythrocyte and its infection
by malaria parasites.
Targeting Erythrocyte Gs
Our previous studies had shown that a peptide designed to
inhibit Gs protein interaction with its receptors blocked
malarial entry into erythrocytes [7]. However, since the
peptide does not diffuse into normal erythrocytes, there
was no evidence that it blocked endogenous Gs function in
Figure 3. Erythrocyte Ghosts Support Malarial Invasion and Growth
(A) LY-D–loaded erythrocyte ghosts (yellow) were infected with P. falciparum (detected by blue DNA stain Hoechst 33342; indicated by arrow). Bar
represents 5 lm.
(B) Ghosts (white bars) or erythrocytes (grey bars) infected at low (left) or high (right) parasitemias were monitored by Giemsa staining of thin blood
smears at the indicated times of infection; mean values are shown. Error bars show standard deviation of triplicate measurements of a representative
experiment.
(C) An infected culture containing 50% ghosts and 50% erythrocytes was monitored for cell type-specific parasitemias by counting the number of
Hoechst 33342–stained parasite nuclei in fluorescent ghosts (white bars) versus non-fluorescent erythrocytes (grey bars) using DIC and fluorescence
microscopy of live cells (see Methods). Error bars show standard deviation of triplicate measurements of a representative experiment.
(D) Giemsa-stained thin blood smears showing ring-, trophozoite-, and schizont-stage parasites in normal (upper) and ghosted (lower) erythrocytes. Bar
represents 5 lm.
(E) Growth of P. falciparum in ghosts (Ghs) or in erythrocytes (RBCs) in culture over multiple life cycles. Parasites were cultured in ghosts (indicated by
dashed line) or in normal erythrocytes (indicated by solid line) for 60 h to ;25% parasitemia, and then were diluted into normal erythrocytes and grown
for an additional 50 h. Parasitemia was assessed by counting Giemsa-stained thin blood smears. Error bars show 95% CIs of duplicate measurements at
each time point.
doi:10.1371/journal.pmed.0030528.g003
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Erythrocyte GS and Malarial Infectionthe red cell. In addition, erythrocytes are terminally differ-
entiated cells, their signaling mechanisms are not well
understood, and direct evidence that erythrocyte G proteins
are active is not available. We therefore introduced the Gs
peptides into ghosts to establish whether it acted on its
designated target Gs. As shown in Figure 4A, Gs peptide
blocked cAMP production in response to the b-AR agonist,
isoproterenol. The extent of this inhibition was comparable
to that seen with propranolol, a b-adrenergic antagonist that
blocks Gs signaling. This inhibitory effect was achieved at 40
lMG s peptide, which is known to be effective at 10–50 lMi n
other cell types [24]. In contrast, the control scrambled
peptide (Gscr) had no effect on cAMP production stimulated
by isoproterenol. These data establish that b-adrenergic
signaling in erythrocytes is mediated through Gs and that
the Gs peptide directly targets and blocks activation of
erythrocyte Gs.
To directly link this inhibition of host Gs to malarial
infection, we assayed the effect of the peptide on parasite
invasion and intracellular maturation in ghosts. As shown in
Figure 4B, Gs peptide blocked malarial invasion at low
micromolar concentrations. Importantly, there was a marked
reduction in infection at the same peptide concentration (40
lM) that blocked Gs activation. In contrast, control Gscr
peptide had no effect on parasite invasion into ghosts, even at
a higher concentration (up to 400 lM, Figure 4B). In addition,
peptides designed to block Gi or Gq proteins also had no
effect on invasion (Figure S1). These data establish that the Gs
peptide can block malarial entry at the same concentrations
that quench receptor-mediated Gs signaling. However,
invasion is not completely abolished, suggesting that there
may be additional mechanisms that regulate entry. Thus, if Gs
only regulates invasion, it may not provide a satisfactory
target for development of antimalarials.
Our results presented in Figure 3 suggest that ghosts
support normal invasion and intracellular development of
parasites, and thus allow us to examine erythrocyte functions
needed in malarial entry as well as intracellular growth. To
determine the requirement of Gs signaling for intraerythro-
cytic parasite growth, we followed the development of rings
formed in the presence of 40 lM peptide to schizogony. As
shown in Figure 4C, at this concentration of peptide, there
was no measurable effect on trophozoites formed, but the
number of schizonts detected was reduced. Since maturing
trophozoites are known to actively ingest as much as 80% of
the erythrocyte cytoplasm, the net intraerythrocytic peptide
concentration at schizont stages of growth may be lower.
Nonetheless, the data presented in Figure 4B and 4C provide
a pharmacological link between the inhibition of host
erythrocyte signaling, malaria parasite invasion, and intra-
erythrocytic development.
A second, independent way of down-regulating Gs signaling
in erythrocytes is by using b-antagonists. The b-blocker
propranolol was previously known to inhibit isoproterenol-
Figure 4. Targeting Erythrocyte Gs Down-Regulates b-Adrenergic Signaling and Inhibits Malarial Infection
(A) Ghosts incubated in 40 lMG s (indicated by hatched bars) or Gscr control peptide (indicated by solid bars) were treated with agonist (isoproterenol
[iso]) and/or antagonist (propranolol [prop]), and cAMP was measured as described in Methods. Error bars show 95% CI of triplicate measurements from
a representative experiment of three independent experiments. The mean baseline cAMP concentration in control ghosts was 1.08 pmol cAMP (95% CI
0.57–1.60 pmol; four experiments) per 1310
8 cells. The maximum isoproterenol-induced cAMP level obtained in control-treated ghosts was 12.45 pmol
cAMP (95% CI 10.20–14.70 pmol) per 1 3 10
8 cells.
(B) Ghosts incubated with Gs peptide ( 40 lM) or Gscr control peptide (up to 400 lM) were assayed for malarial invasion. Data are represented as
percentage inhibition relative to control cultures treated with equimolar concentrations of control peptide. Three experiments in triplicate for each data
point except 10 lM (two experiments in triplicate). Error bars show 95% CI for all experiments; asterisks indicate p , 0.001 compared to 400 lM control
Gscr peptide–treated cultures.
(C) Parasites in ghosts were incubated with the indicated concentrations of peptide and monitored at 15, 32, and 44 h after invasion by examination of
Giemsa-stained thin blood smears. The number of ring (R)–, trophozoite (T)–, and schizont (S)–stage parasites per 1,000 total ghosts at each time point
are shown; numbers in parentheses indicate the standard deviation of triplicate measurements from one experiment; a total of two experiments were
carried out.
doi:10.1371/journal.pmed.0030528.g004
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Erythrocyte GS and Malarial Infectionmediated stimulation of invasion at ;10 lM [7], but effects on
P. falciparum intracellular maturation and growth were not
studied. In standard growth assays, we found that propranolol
inhibited [
3H]-labeled hypoxanthine uptake by half (IC50)a t
1.2 lM and by 90% inhibitory concentration (IC90) at 7.1 lM
(Figure 5A). Since hypoxanthine incorporation is a standard
measure of parasite proliferation, the data conﬁrm that, in
addition to invasion, propranolol can block one or more
processes needed for intracellular parasite survival. The
inactive isomer of propranolol was not inhibitory, suggesting
that the antimalarial effect of racemic propranolol is due to
speciﬁc down-regulation of erythrocyte Gs signaling. Exami-
nation of Giemsa-stained slides from treated cultures (Figure
5B) showed that 2 lM propranolol blocked intracellular
maturation of parasites to the schizont stage. At 2 lM,
propranolol had no signiﬁcant effect on invasion, which is
consistent with our earlier data indicating that signiﬁcant
inhibition of invasion required ;10 lM drug [7]. Hence, the
observed IC50 of 1.2 lM suggests that most of the inhibitory
activity of propranolol is due to blockage of intracellular
parasite maturation. Other b2-antagonists such as ICI118,551
and alprenolol also blocked parasite growth, as measured by
hypoxanthine incorporation (Figure 5C). One b1/b2–antago-
nist, nadolol, was ineffective at 10 lM. All three b1-speciﬁc
antagonists had no effect, and this may reﬂect a lack of b1-
adrenergic receptors on the erythrocyte. The three most
active b-antagonists (including propranolol) appear to show
IC50 values of between 1 and 10 lM. Testing additional b-
antagonists (particularly b2 antagonists) may yield additional
active inhibitors.
To examine intraerythrocytic process(es) that may be
inhibited by propranolol treatment, we tested several general
functions of malaria parasites. First, we tested the sensitivity
of control and propranolol-treated parasites to lysis in the
presence of 5% sorbitol, which is known to be actively
imported into trophozoite- and schizont-stage parasites—
likely via the plasmodial nutrient transport channel PESAC
[25]. No difference was found between control and drug-
treated parasites (Figure 6A), suggesting that maturation to
the trophozoite stage occurred in both 2 and 10 lM
propranolol-treated infected cells. Second, export of a
parasite-encoded protein PfHRPII fused to GFP to the
erythrocyte [13] was not blocked by either 2 or 10 lM
propranolol (Figure 6B), suggesting that the drug did not act
by altering protein export to host cells. Nonetheless,
examination of the morphology of 2 lM propranolol-treated
Figure 5. b-Blockers Inhibit Maturation of P. falciparum in In Vitro Cultures
(A) [
3H]-hypoxanthine incorporation of P. falciparum 3D7 when treated with racemic propranolol (indicated by black diamonds) or its inactive isomer
(indicated by grey squares). Error bars show the standard deviation of triplicate measurements. IC50 values were determined by fitting the data as
described in Methods; the IC50 value obtained for racemic propranolol (1.2 lM; 95% CI 1.0–1.6 lM) is shown. Three experiments; hatched sign indicates
p , 0.001; asterisks indicate p , 0.03 compared to equimolar inactive propranolol.
(B) Effect of 2 lM propranolol on intracellular growth in normal erythrocytes. Mock- and drug-treated cultures were monitored at 15, 32, and 44 h after
invasion by examination of Giemsa-stained thin blood smears. The number of ring (R)–, trophozoite (T)–, and schizont (S)–stage parasites per 1,000 total
erythrocytes at each time point are shown; numbers in parentheses indicate the standard deviation of triplicate measurements from one experiment;
the total number of experiments was three.
(C) [
3H]-hypoxanthine incorporation of P. falciparum 3D7–infected erythrocytes treated with 1 or 10 lM concentrations of adrenergic-acting drugs
(nonspecific b1/b2–antagonists: propranolol, alprenolol, and nadolol; b2-specific antagonists: ICI118,551 and butoxamine; b1-specific antagonists:
acebutalol, atenolol, and metoprolol; and a2-specific agonist [ag]: clonidine). Chloroquine (50 nM) was used as an inhibitory control. Triplicate samples;
asterisks denote a treatment with p , 0.001 compared to control-treated cultures.
doi:10.1371/journal.pmed.0030528.g005
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Erythrocyte GS and Malarial Infectionparasites at 44 h post-invasion (Figure 6C) revealed a lack of
the segmented, mature schizonts characteristically found in
control cultures at 44 h. Control cultures also showed the
presence of new rings (marked by an asterisk in Figure 5B)
indicating their acceleration past segmented schizonts to new
rings. (This variation of the 48-h intraerythrocytic cycle is
frequently observed in culture.) The effect of propranolol on
parasite morphology was greater at 10 lM (compared to 2
lM), but the precise nature of one or more steps regulated by
Gs signaling and needed for maturation to the schizont stage
remains unknown.
Inhibitors of Erythrocyte Gs Signaling May Be Useful as
Novel Antimalarial Therapeutics
The emergence of drug-resistant parasites has led to the
need for combinations of two or more antimalarials to
improve microbial killing and reduce further resistance.
Propranolol was therefore combined and tested with two
widely used antimalarials, chloroquine and artemisinin. IC50
values were ﬁrst independently determined for each individ-
ual drug in P. falciparum 3D7 and/or FCB strains (Figure S2).
Using those values, ﬁxed ratios of propranolol:chloroquine
(or propranolol:artemisinin) were tested by in vitro hypo-
xanthine assays [16]. When used in combination against P.
falciparum strain 3D7, propranolol reduced the amount of
chloroquine required to achieve an IC90 dose by .1 log
(Figure 7A and Table S1; the 3:1 and 1:1 propranolol:chlor-
oquine combinations had 11- and 4-fold effects, respectively).
Isobologram analysis (Figure S3) indicated that there was an
additive antimalarial effect between propranolol and chlor-
oquine. Similar results were found for this combination
against the more resistant P. falciparum FCB (Figures 7B and
S3). Propranolol did not reverse chloroquine resistance, but
did reduce the effective dose in the resistant (FCB) and
sensitive (3D7) strains. This result was different than the well-
known chloroquine reversal seen in previous ﬁxed-ratio drug
combinations using chloroquine and the calcium-channel
blocker verapamil [16]. Importantly, this b-blocker did not
antagonize chloroquine against either strain, suggesting that
blocking Gs function may enable utilization of chloroquine at
lower concentrations and thus may facilitate its use against
resistant parasites.
Artemisinin is a newer, schizonticidal antimalarial that is
gaining acceptance for treatment of severe and uncompli-
cated malaria because of its rapid action and lower
prevalence of resistance [26,27]. Its mode of action is thought
to be distinct from that of chloroquine [28]. When used in
combination, propranolol also reduced the amount of
artemisinin required to achieve an effective dose 5-fold
(Figure 7C) and acted in a potent, additive fashion (Figure S3;
Table S1). Since propranolol was additive with two distinct
drugs, it may be effective when combined with a range of
Figure 6. Analysis of the Maturation Defect in Propranolol-Treated Parasites
(A) Effect of propranolol on sorbitol sensitivity of infected erythrocytes. Normal or infected erythrocytes were mock-treated or incubated with 2 or1 0
lM propranolol for 30 h and then resuspended in 5% sorbitol as described in Methods. Bars represent percentage lysis as calculated by the hemoglobin
absorbance (570 nm) of the supernatant after 0 and 15 min of sorbitol treatment divided by the hemoglobin absorbance of a saponin-treated sample
(where 100% of hemoglobin is released) from the same culture. Error bars show the standard deviation from triplicate samples.
(B) Effect of propranolol on export of a parasite-encoded protein (PfHRPII) fused to GFP to the host erythrocyte. Fluorescence micrographs of infected
erythrocytes that were mock-treated or exposed to 2 or 10 lM propranolol for 30 h (see Methods) are shown, with single optical sections. Bar
represents 5 lm. The fraction of GFP exported to the erythrocyte (e) from the parasite (p) was determined (see Methods) and is relatively unchanged by
drug treatment. Error bars show the standard deviation from ten samples per treatment.
(C) Giemsa-stained thin blood smears showing the morphology of parasites when infected erythrocytes were treated with 2 or 10 lM propranolol for
15, 32, and 44 h of culture. Infected erythrocytes treated with 2 lM propranolol showed significant retardation in schizont formation by 44 h. At 10 lM
propranolol, a growth defect was observed by 32 h post-invasion. Bar represents 3 lm; all images are displayed at the same scale.
doi:10.1371/journal.pmed.0030528.g006
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doses.
Our previous results suggested that the requirement for
host signaling via b-ARs and Gs was conserved across parasite
species. We therefore further tested propranolol-containing
drug combinations in the P. berghei ANKA mouse model of
malarial infection. When tested alone in mice, the IC50 of
racemic propranolol was 7.5 mg/kg/d [7]. As shown in Figures
7D and S3, a combination of 2:1 propranolol:chloroquine
reduced the IC50 of chloroquine from 1.64 to 0.66 mg/kg/d.
The 1:1 and 1:2 propranolol:chloroquine combinations had
less effect. This ﬁnding is in contrast to our results in vitro
where 1:1 propranolol:chloroquine combinations had a 4-
fold effect. This discrepancy may be due to the fact that the
half-life of propranolol is 3–4 h [29,30], and therefore
multiple treatments and/or more stable compounds may
prove more effective. Furthermore, since mice metabolize
drugs at higher levels than humans [31,32], mouse-derived
data likely overestimate the amount of drug required in
humans. Importantly, as in in vitro studies, the combinations
tested were not antagonistic (Figure S3). Thus, both our in
vitro and in vivo data suggest that targeting erythrocyte Gs in
combination with existing antimalarial drugs may have
therapeutic potential and may reduce the amount of existing
drug needed to effectively treat patients.
Discussion
In this paper, we describe the development of erythrocyte
‘‘ghosts’’ active in b-adrenergic signaling that support robust
P. falciparum growth in culture. With this system, we show that
aG s peptide inhibits activation of erythrocyte b-AR signaling
by b-agonists, providing deﬁnitive evidence that the peptide
targets erythrocyte Gs signaling. At the same pharmacological
concentrations, the peptide signiﬁcantly inhibits malarial
invasion of ghosts as well as intracellular maturation of
parasites. Furthermore, we ﬁnd that inhibiting Gs signaling
with b-blockers also inhibits intracellular parasite growth.
Finally, we show that a b-blocker such as propranolol can be
used to reduce doses of existing antimalarials in both in vitro
and in vivo infections. We therefore establish that Gs offers a
host target to ﬁght infection and to develop new antimalarial
chemotherapies.
Erythrocyte ghost preparations have been described
previously for studying the erythrocyte membrane and
Figure 7. Propranolol Inhibits Malarial Growth in Combination with Existing Antimalarial Drugs
(A) [
3H]-hypoxanthine incorporation (see Methods) of P. falciparum 3D7 treated with chloroquine alone (CQ, indicated by black diamonds) or with ratios
of both drugs (CQ:propranolol, 3:1 [black spheres]; 1:1 [grey triangles]; and 1:3 [grey squares]). Error bars show standard deviation of triplicate samples.
IC50 values were determined by fitting the data as described in Methods. IC50 CQ alone: 28.9 nM (95% CI 22.3–36.6 nM). The IC50 CQ values when treated
with combinations of both drugs in different ratios of CQ:propranolol were as follows: 3:1, 14.7 nM (95% CI 11.9–18.1 nM); 1:1, 5.9 nM (95% CI 4.9–7.0.6
nM); and 1:3, 2.9 nM (95% CI 2.5–3.2 nM).
(B) [
3H]-hypoxanthine incorporation of P. falciparum chloroquine-resistant FCB strain treated with chloroquine alone (CQ, indicated by black diamonds)
or with ratios of both drugs (CQ:propranolol, 3:1 [black spheres]; 1:1 [grey triangles]; and 1:3 [grey squares]). Error bars show standard deviation of
triplicate samples. IC50 values were determined by fitting the data as described in Methods. IC50 CQ alone: 63.2 nM (95% CI 52.4–76.4 nM). The IC50 CQ
values when treated with combinations of both drugs in different ratios of CQ:propranolol were as follows: 3:1, 26.7 nM (95% CI 24.6–29.0 nM); 1:1, 9.7
nM (95% CI 9.3–10.1 nM); and 1:3, 6.0 nM (95% CI 5.8–6.2 nM).
(C) [
3H]-hypoxanthine incorporation of P. falciparum 3D7 treated with artemisinin alone (black diamonds) or with ratios of both drugs
(artemisinin:propranolol, 3:1 [black spheres]; 1:1 [grey triangles]; and 1:3 [grey squares]). Error bars show standard deviation of triplicate samples.
IC50 values were determined by fitting the data as described in Methods. IC50 artemisinin alone: 3.2 nM (95% CI 2.9–3.6 nM). The IC50 artemisinin values
when treated with combinations of both drugs in different ratios of artemisinin:propranolol were as follows: 3:1, 2.3 nM (95% CI 2.0–2.6 nM); 1:1, 1.3 nM
(95% CI 1.2–1.4 nM); and 1:3, 0.56 nM (95% CI 0.5–0.6 nM).
(D) Combinations of propranolol with chloroquine (CQ) in a 4-d Peter’s test of P. berghei ANKA–infected Balb/c mice (see Methods). IC50 CQ alone: 1.6
mg/kg/d (95% CI 1.2–2.2 mg/kg/d). The IC50 CQ values when treated with combinations of both drugs in different ratios of CQ:propranolol were as
follows: 2:1, 1.2 mg/kg/d (95% CI 1.0–1.4 mg/kg/d); 1:1, 1.0 mg/kg/d (95% CI 0.8–1.3 mg/kg/d); and 1:2, 0.7 mg/kg/d (95% CI 0.4–1.0 mg/kg/d). Error bars
show standard deviation of measurements from five mice per treatment group.
doi:10.1371/journal.pmed.0030528.g007
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Erythrocyte GS and Malarial Infectioncytoskeleton and malarial infection [33–38]. However, ma-
larial infection rates of earlier ghosts were either untested or
lower than in normal erythrocytes. In contrast, the ghosts
described here retained mature erythrocyte double-discoidal
morphology, Gs signaling responses, and support of robust
malarial infection. Several differences between our proce-
dure and procedures described in prior reports include the
lysis of erythrocytes in 3.5-kDa MWCO dialysis membranes
rather than in 12–14-kDa MWCO membranes used previ-
ously, and our use of a potassium-rich resealing buffer rather
than isotonic saline. Dialysis pore size may be critical since a
10–13-kDa dialyzable, cytoplasmic erythrocyte protein was
reported necessary for malarial invasion of ghosts [39,40].
Prior studies did not include GTP, which was incorporated
here to ensure the support of a GTP cycle. Ghosts prepared in
this manner can be loaded with a variety of peptidic,
proteinaceous, ﬂuorescent, or other cargoes and are likely
suitable for studying many aspects of erythrocyte function
and malarial infection. We have used them to deﬁnitively
establish that erythrocyte b-adrenergic signaling is indeed
mediated by Gs and thus to explain why inhibitors of
receptor-mediated Gs signaling (such as propranolol) block
malaria parasite invasion and intracellular growth. The
ﬁndings strongly support the possibility that the erythrocyte
Gs pathway might be targeted to treat malaria.
The concept of host-targeted therapies for treating
infectious diseases has only emerged recently and, to the
best of our knowledge, is unexplored for parasitic infections.
Since malaria parasites must invade host cells to proliferate,
host pathways necessary for parasite survival present oppor-
tunities for intervention. Here we have shown that targeting
erythrocyte Gs inhibits parasite growth within erythrocytes as
well as at the initial entry event. One obvious possible
disadvantage of host-targeted therapy is potential toxicity to
the host since Gs regulates many cellular pathways by
modulating transcription factors, ion channels, metabolic
enzymes, and other molecules [41]. However, Gs signaling
alone is insufﬁcient to drive vacuole formation (e.g., vacuoles
do not form in isoproterenol-treated erythrocytes), and
therefore parasite components are expected to engage this
host signaling pathway during invasion [42]. Other parasite
proteins may interact with this pathway during intracellular
growth. Thus, optimal inhibitors should target interactions
between host Gs and parasite proteins, and these may have
signiﬁcantly reduced toxicity, particularly if they can be made
additionally selective for erythrocyte Gs. The wide array of
pharmacological GPCR-inhibitors currently available suggest
chemical backbones that may be useful in rational design of
such antimalarials.
In addition, antihypertensive drugs that down-regulate Gs
via host receptors (i.e., b-blockers such as the ﬁrst-generation
drug propranolol) are extremely well-tolerated, partly be-
cause the host can adapt to drug treatment by producing
additional adrenergic receptors and Gs. Since the mature
erythrocyte is incapable of de novo protein synthesis, it
cannot mount such an adaptive response. Thus, erythrocytes
may be more vulnerable to inhibition of b-AR/Gs signaling,
while other host tissues could adapt to avoid toxicity. A well-
developed, host-targeted antimicrobial therapy directed at
human chemokine receptor 5 (CCR5) for the treatment of
drug-resistant HIV is currently in clinical trials. Short-term
treatment with CCR5 antagonists reduced viral loads in
infected patients [43], prov i d i n gp r o o fo fc o n c e p tf o r
targeting a host determinant to treat a major infectious
disease.
Malaria is a major threat to global health, and there is an
imperative to use existing drugs to treat patients while the
search for vaccines and better drugs continues. Development
of a new drug is expensive and can take more than a decade
[44]. Propranolol and a wide range of b-blockers are currently
approved for human use. In humans, racemic propranolol is
typically prescribed at ;60–320 mg/d (;0.8–4.5 mg/kg/d in an
average 70-kg person) [45] with a maximum clinical dose of
;10 mg/kg/d. The maximum concentration of propranolol in
blood approaches 1 lM [29], and thus it is likely that
treatments can be designed that achieve IC50s in the blood-
stream (0.4–1.2 lM in the work discussed in this paper; 0.4
lM, Drug Screening Program, Strategic and Discovery
Research UNICEF/UNDP/World Bank/WHO Special Pro-
gramme for Research and Training in Tropical Diseases,
personal communication) using a range of dosages compara-
ble to those used for hypertension. Furthermore, higher
concentrations of the drug can also be administered [45].
Malaria patients may be hypotensive [46], and therefore
treatment with b-blockers must be considered carefully.
However, at normal dosages, propranolol does not usually
cause orthostatic hypotension because the a-adrenergic
system maintains peripheral vasoconstriction [47,48]; some
patients may show mild orthostatic hypotension [49]. Other
quinoline antimalarials (e.g., quinine and meﬂoquine) may
also exacerbate orthostatic hypotension in malaria patients
[46,50]. The main cause of hypotension in malaria patients is
acidosis secondary to hypovolemia, which can be managed
with intravenous saline. Propranolol has been found to
mitigate some hyper-adrenergic effects that occur in patients
with shock secondary to hypovolemia. In such cases, b-
adrenergic blockade by propranolol is thought to reduce
muscle lactate production and to limit metabolic acidosis
[51,52]. Thus, this drug may have unseen beneﬁts for clinically
ill patients.
As with any new drug, care would obviously need to be
taken in any clinical malaria study using propranolol-
containing combinations. Propranolol is contraindicated for
use with the quinoline antimalarial quinidine [47], which also
has a-adrenergic–blocking activities [53]. Other quinoline
antimalarials (e.g., quinine and meﬂoquine) that exacerbate
orthostatic hypotension also produce electrocardiographic
abnormalities (i.e., long corrected QT interval), although not
of the severity seen with halofantrine [54]. There is one report
of a patient with a previous myocardial infarction who was
taking propranolol and suffered a cardiopulmonary arrest 5 h
after taking a single dose of meﬂoquine; the patient made a
full recovery [55]. Meﬂoquine and propranolol are also
associated independently with depression. Thus, some quino-
lines may be contraindicated for use with propranolol.
However, only minor, asymptomatic corrected QT interval
disturbances are found with other antimalarial drugs such as
chloroquine (a quinoline) [56], sulfadoxine-pyrimethamine
[57], and artemisinin [58]; no electrocardiographic changes
were associated with atovaquone-proguanil alone or in
combination with artemisinin [59]. Overall, propranolol has
few serious side effects, is recommended for use in pregnant
women, is widely approved by regulatory agencies, and is
frequently taken for life.
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Erythrocyte GS and Malarial InfectionIn addition to its safety and efﬁcacy, propranolol is made
even more attractive by its low off-patent cost, high stability,
and ease of production. In addition, second- and third-
generation b-blockers have been developed, and all gener-
ations of b-blockers are routinely taken for many years to
treat chronic conditions. Thus, it may be an appropriate time
to evaluate combinations containing b-blockers to treat
human clinical infections that fail to respond to optimized
antimalarial therapy.
Supporting Information
Figure S1. Gi- and Gq-Speciﬁc Peptides Do Not Inhibit Malarial
Invasion of Ghosts
Erythrocyte ghosts were incubated with 50 lM control Gscr,G s,G i,o r
Gq peptides and tested for invasion as described in Methods. Error
bars show standard deviations across three experiments in triplicate.
Found at doi:10.1371/journal.pmed.0030528.sg001 (52 KB PPT).
Figure S2. [
3H]-Hypoxanthine Assays to Determine In Vitro IC50
Values of Individual Drugs Used in This Study
IC50s for each drug were determined in chloroquine-sensitive (3D7)
and chloroquine-resistant (FCB) P. falciparum by in vitro [
3H]-
hypoxanthine incorporation (see Methods). IC50 values were deter-
mined by ﬁtting the data as described in Methods; each data point is
shown in triplicate. Asterisks denote p , 0.05; hash marks denote p ,
0.01; crosses denote p , 0.001. CQ, chloroquine; Art, artemisinin;
Prop, propranolol.
Found at doi:10.1371/journal.pmed.0030528.sg002 (127 KB PPT).
Figure S3. Propranolol Functions Additively with Existing Antima-
larials In Vitro and In Vivo
Isobolograms (see Methods) are presented for in vitro studies of
propranolol and chloroquine ([A], in 3D7 strain; [B], in FCB strain)
and propranolol and artemisinin ([C], in 3D7 strain), and an in vivo
study of propranolol and chloroquine in the P. berghei ANKA mouse
model of malarial infection (D).
Found at doi:10.1371/journal.pmed.0030528.sg003 (184 KB PPT).
Table S1. Effects of Propranolol-Containing Drug Combinations on
Growth of P. falciparum and P. berghei
Found at doi:10.1371/journal.pmed.0030528.st001 (20 KB XLS).
Accession Numbers
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the proteins discussed in this paper are human b2-AR (P07550);
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(P29992); human heterotrimeric Gs (P63092); and PfHRPII (P90582).
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Editors’ Summary
Background. New drugs for treatment of malaria are urgently needed,
because the malaria parasite has evolved resistance against virtually all
types of commonly used drugs. When a person is bitten by a malaria-
infected mosquito, the parasite first infects the person’s liver cells before
going on to infect red blood cells, where the parasites multiply and
develop into a parasite stage called a schizont. The red blood cells then
burst and release more schizonts into the bloodstream; it is this ‘‘blood
stage’’ of infection in humans that causes the symptoms of disease.
Therefore efforts to develop new drugs against malaria often focus on
this ‘‘blood stage’’ of infection. One strategy for developing new drugs is
termed the ‘‘host-targeted’’ approach. This means that rather than trying
to block processes occurring within the parasite itself, a drug can be
developed which blocks processes within the person’s red blood cells,
and which would otherwise be needed for the parasite to complete its
life cycle. It will be difficult for malaria parasites to evolve resistance to
such a drug, because changes in a person’s red blood cells occur much
more slowly than in the parasites themselves.
Why Was This Study Done? This research group has been studying a
set of molecular processes within human red blood cells which seemed
to be required for entry of malaria parasites into the cells. They wanted
to get a better understanding of those processes and, specifically, to find
out whether it would be possible to use particular molecules to block
those processes, and by doing so to prevent malaria parasites from
entering and multiplying within red blood cells. In particular, when the
malaria parasites invade the red blood cell, they form membranes
around the red blood cell, containing lipids and proteins ‘‘hijacked’’ from
the red blood cell membrane. These researchers already knew that two
particular proteins were hijacked in this way; the b2-adrenergic receptor
(b2-AR) and heterotrimeric G protein (Gs). These two proteins act
together to pass messages across the surface of the membrane to inside
the cell. Small molecules could be used to block signaling through b2-AR
and Gs, and therefore potentially to provide a new way of preventing
malaria parasites from entering red blood cells and multiplying within
them.
What Did the Researchers Do and Find? Firstly, the researchers made
red blood cell ‘‘ghosts’’ in which to study these molecular processes. This
meant that they took fresh red blood cells from healthy human
volunteers, burst them to remove half the contents and loaded them
with markers and other cargoes before resealing the membranes of the
cell. These resealed markers and cargoes allowed them to see what was
happening inside the cells. Malaria parasites were able to invade these
ghosts normally and multiply within them. When the researchers
introduced a specific peptide (a molecule consisting of a short series
of amino acids), they found that it blocked Gs signaling within the
ghosts. This peptide also prevented malaria parasites from developing
inside the ghosts. Therefore, they concluded that Gs signaling inside the
red blood cell was important for the parasite life cycle. The researchers
then examined a drug called propranolol which is already known to act
on Gs signaling and which is commonly prescribed for high blood
pressure. This drug also blocked development of malaria parasites inside
the ghosts when used at a particular concentration. Finally, the
researchers studied the effect of giving propranolol, along with other
antimalarial drugs, to human malaria parasites in a culture dish and to
mice injected with a malaria parasite that infects rodents. In these
experiments, adding propranolol reduced the amount of other ‘‘parasite-
targeted’’ drugs that were needed to effectively treat malarial infection
in tissue culture and in mice.
What Do These Findings Mean? Showing that the Gs signaling pathway
is important for the malaria parasite’s life cycle opens up new
possibilities for drug development. Specifically, propranolol (which is
already approved for treatment of high blood pressure and other
conditions) might itself provide a new candidate therapy, either alone or
in combination with existing drugs. These combinations would first,
however, need to be tested in human clinical trials, perhaps by seeing
whether they have antimalarial activity in people who have not
responded to existing antimalarial drugs. Since it acts to lower blood
pressure, which can already be low in some people with malaria, there
are some concerns that propranolol might not be a suitable drug
candidate for use, especially with existing antimalarial drugs that also
reduce blood pressure. However, other molecules which block Gs
signaling could be tested for activity against malaria should propranolol
prove not to be an ideal drug candidate.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0030528.
  The World Health Organization publishes a minisite containing links to
information about all aspects of malaria worldwide, including
treatment, prevention, and current programs for malaria control
  Medicines for Malaria Venture is a collaboration between public and
private organizations (including the pharmaceutical industry) that
aims to fund and manage the development of new drugs for
treatment and prevention of malaria
  Wikipedia entries for drug discovery and drug development (Wikipedia
is an internet encyclopedia that anyone can edit)
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